NEW YORK (GenomeWeb) – BGI and Clearbridge BioMedics said today that they have signed a partnership agreement, under which they will solely distribute and market Clearbridge's ClearCell FX1 solution and related liquid biopsy products in China.

BGI said that it also hopes to use its genomics expertise and capabilities to extend Clearbridge's ClearCell FX1 circulating tumor cell system into new clinical research applications, as well as develop specific clinical products using the platform.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.